BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

350 related articles for article (PubMed ID: 31789476)

  • 21. Post-gemcitabine therapy for patients with advanced pancreatic cancer - A comparative review of randomized trials evaluating oxaliplatin- and/or irinotecan-containing regimens.
    Vogel A; Ciardiello F; Hubner RA; Blanc JF; Carrato A; Yang Y; Patel DA; Ektare V; de Jong FA; Gill S
    Cancer Treat Rev; 2016 Nov; 50():142-147. PubMed ID: 27676174
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The Impact of Liposomal Irinotecan on the Treatment of Advanced Pancreatic Adenocarcinoma: Real-World Experience in a Taiwanese Cohort.
    Su YY; Chiang NJ; Tsai HJ; Yen CJ; Shan YS; Chen LT
    Sci Rep; 2020 May; 10(1):7420. PubMed ID: 32366911
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical outcomes of liposomal irinotecan plus fluorouracil/leucovorin for metastatic pancreatic adenocarcinoma in patients previously treated with conventional irinotecan-containing chemotherapy.
    Bang K; Cheon J; Jeong JH; Im HS; Kim KP; Ryoo BY; Yoo C
    Ther Adv Med Oncol; 2021; 13():17588359211003053. PubMed ID: 33796153
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Nal-IRI with 5-fluorouracil (5-FU) and leucovorin or gemcitabine plus cisplatin in advanced biliary tract cancer - the NIFE trial (AIO-YMO HEP-0315) an open label, non-comparative, randomized, multicenter phase II study.
    Perkhofer L; Berger AW; Beutel AK; Gallmeier E; Angermeier S; Fischer von Weikersthal L; Goetze TO; Muche R; Seufferlein T; Ettrich TJ
    BMC Cancer; 2019 Oct; 19(1):990. PubMed ID: 31646981
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Nal-IRI/5-FU/LV versus modified FOLFIRINOX and FOLFIRI as second-line chemotherapy for unresectable pancreatic cancer: A single center retrospective study.
    Tezuka S; Ueno M; Kobayashi S; Hamaguchi T; Yamachika Y; Oishi R; Nagashima S; Fukushima T; Morimoto M; Shin M
    Pancreatology; 2022 Sep; 22(6):789-796. PubMed ID: 35705458
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Liposomal Irinotecan: A Review in Metastatic Pancreatic Adenocarcinoma.
    Lamb YN; Scott LJ
    Drugs; 2017 May; 77(7):785-792. PubMed ID: 28401446
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Real-World Dosing Patterns and Outcomes of Patients With Metastatic Pancreatic Cancer Treated With a Liposomal Irinotecan Regimen in the United States.
    Barzi A; Miksad R; Surinach A; Corvino FA; Wang S; Torres AZ; Mamlouk K; Pulgar S; Valderrama A; Bekaii-Saab T; Ahn D
    Pancreas; 2020 Feb; 49(2):193-200. PubMed ID: 32011529
    [TBL] [Abstract][Full Text] [Related]  

  • 28. First evidence for the antitumor activity of nanoliposomal irinotecan with 5-fluorouracil and folinic acid in metastatic biliary tract cancer.
    Taghizadeh H; Unseld M; Schmiderer A; Djanani A; Wilthoner K; Buchinger D; Prager GW
    Cancer Chemother Pharmacol; 2020 Jul; 86(1):109-115. PubMed ID: 32556829
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Inhibition of TGF-β signalling in combination with nal-IRI plus 5-Fluorouracil/Leucovorin suppresses invasion and prolongs survival in pancreatic tumour mouse models.
    Hong E; Park S; Ooshima A; Hong CP; Park J; Heo JS; Lee S; An H; Kang JM; Park SH; Park JO; Kim SJ
    Sci Rep; 2020 Feb; 10(1):2935. PubMed ID: 32076068
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinical outcomes of liposomal irinotecan in advanced pancreatic adenocarcinoma patients previously treated with conventional irinotecan-based chemotherapy: a real-world study.
    Gupta A; De Jesus-Acosta A; Zheng L; Lee V; Kamel I; Le D; Pishvaian M; Laheru D
    Front Oncol; 2023; 13():1250136. PubMed ID: 37700832
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Treatment outcomes of nanoliposomal irinotecan as second-line chemotherapy after gemcitabine and nab-paclitaxel in metastatic and recurrent pancreatic cancer.
    Mie T; Sasaki T; Okamoto T; Takeda T; Mori C; Furukawa T; Kasuga A; Matsuyama M; Ozaka M; Sasahira N
    Jpn J Clin Oncol; 2022 Dec; 52(12):1399-1407. PubMed ID: 36111430
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Nomogram for Predicting Survival in Patients Treated with Liposomal Irinotecan Plus Fluorouracil and Leucovorin in Metastatic Pancreatic Cancer.
    Chen LT; Macarulla T; Blanc JF; Mirakhur B; Jong FA; Belanger B; Bekaii-Saab T; Siveke JT
    Cancers (Basel); 2019 Jul; 11(8):. PubMed ID: 31357748
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Real-world efficacy and safety of liposomal irinotecan plus fluorouracil/leucovorin in patients with metastatic pancreatic adenocarcinoma: a study by the Korean Cancer Study Group.
    Yoo C; Im HS; Kim KP; Oh DY; Lee KH; Chon HJ; Kim JH; Kang M; Kim I; Lee GJ; Oh SY; Choi Y; Choi HJ; Kim ST; Park JO; Ryoo BY
    Ther Adv Med Oncol; 2019; 11():1758835919871126. PubMed ID: 31489036
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial.
    Wang-Gillam A; Li CP; Bodoky G; Dean A; Shan YS; Jameson G; Macarulla T; Lee KH; Cunningham D; Blanc JF; Hubner RA; Chiu CF; Schwartsmann G; Siveke JT; Braiteh F; Moyo V; Belanger B; Dhindsa N; Bayever E; Von Hoff DD; Chen LT;
    Lancet; 2016 Feb; 387(10018):545-557. PubMed ID: 26615328
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A real-world analysis of nanoliposomal-irinotecan with 5-fluorouracil and folinic acid as third- or later-line therapy in patients with metastatic pancreatic adenocarcinoma.
    Chun JW; Woo SM; Lee SH; Choi JH; Park N; Kim JS; Cho IR; Paik WH; Lee WJ; Ryu JK; Kim YT
    Ther Adv Med Oncol; 2022; 14():17588359221119539. PubMed ID: 36062047
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparison of conventional versus liposomal irinotecan in combination with fluorouracil for advanced pancreatic cancer: a single-institution experience.
    Tossey JC; Reardon J; VanDeusen JB; Noonan AM; Porter K; Arango MJ
    Med Oncol; 2019 Sep; 36(10):87. PubMed ID: 31494781
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Liposomal irinotecan plus fluorouracil/leucovorin versus FOLFIRINOX as the second-line chemotherapy for patients with metastatic pancreatic cancer: a multicenter retrospective study of the Korean Cancer Study Group (KCSG).
    Park HS; Kang B; Chon HJ; Im HS; Lee CK; Kim I; Kang MJ; Hwang JE; Bae WK; Cheon J; Park JO; Hong JY; Kang JH; Kim JH; Lim SH; Kim JW; Kim JW; Yoo C; Choi HJ
    ESMO Open; 2021 Apr; 6(2):100049. PubMed ID: 33578192
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy and tolerability of the combination of nano-liposomal irinotecan and 5-fluorouracil/leucovorin in advanced pancreatic adenocarcinoma: post-approval clinic experience.
    Kasi A; McGinnis T; Naik G; Handa S; Williams G; Paluri R
    J Gastrointest Oncol; 2021 Apr; 12(2):464-473. PubMed ID: 34012640
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Irinotecan plus fluorouracil/leucovorin for metastatic colorectal cancer: a new survival standard.
    Saltz LB; Douillard JY; Pirotta N; Alakl M; Gruia G; Awad L; Elfring GL; Locker PK; Miller LL
    Oncologist; 2001; 6(1):81-91. PubMed ID: 11161231
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Is There Room for Liposomal Irinotecan in Biliary Tract Cancer? A Meta-analysis of Randomised Trials.
    Merz V; Messina C; Zecchetto C; Quinzii A; Frisinghelli M; Trentin C; Salati M; Caffo O; Melisi D
    Clin Oncol (R Coll Radiol); 2024 Feb; 36(2):87-97. PubMed ID: 38129199
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.